Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Completed 51Unknown 22Recruiting 15Terminated 9Withdrawn 7Active not recruiting 7Not yet recruiting 4Available 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 15Gastrointestinal 7Tumor-Agnostic 4Gynecologic 2Thoracic 1Breast 1

Conditions

Neoplasms 140Neoplasm Metastasis 27Carcinoma 5Neoplasm, Residual 4Adenocarcinoma 4Carcinoma, Squamous Cell 3Neoplasms, Unknown Primary 2Neoplasms, Second Primary 2

Interventions

Oxaliplatin 3Capecitabine 2tislelizumab 1Radiotherapy 1Negative-Pressure Wound Therapy 1Leucovorin 1Injections 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Adenocarcinoma × Tumor-Agnostic × Clear all
NCT07489820 2026-05-22

AAPICO

Centre Hospitalier Departemental Vendee

Phase NA Not yet recruiting
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07118800 2025-08-12

NACRE-2

UNICANCER

Phase 3 Not yet recruiting
160 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT06942767 2025-04-27

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡